(firstQuint)Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors.

 This study will initially treat up to approximately 300 patients with advanced solid tumors at approximately 30 sites, worldwide.

 The study will be composed of a dose-limiting toxicity (DLT) assessment phase (Part A) and an expansion phase (Part B).

.

 Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors@highlight

This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab tremelimumab in combination with chemoradiation in patients with advanced solid tumors.

